Search results.

Pemvidutide and survodutide are separate investigational once-weekly GLP-1/glucagon dual agonists with no head-to-head trial. Pemvidutide has a completed Phase 2 obesity study, a completed Phase 2b MASH study, and a planned MASH Phase 3 program. Survodutide has an active Phase 3 program with reported 76-week obesity results and liver-focused studies. Neither is approved for marketing. Their receptor labels overlap, but the molecules, development priorities, doses, populations, durations, efficacy analyses, and gastrointestinal discontinuation records differ, so they are not interchangeable and the available percentages cannot name a winner.

Download 268 deduplicated registry records with named programs, status, phase, enrollment, completion dates, results availability, 53 countries, 1,840 recruiting cities, postal areas, registry geocoordinates, and direct NCT sources.

Search 268 ClinicalTrials.gov records across 13 peptide and next-generation weight-loss programs by status, phase, country, US state, city, postal code, sponsor, intervention, alias, or NCT ID.

Search 40 peptide records and 138 aliases, then answer FDA status, linked clinical trials, clinical evidence, price comparison, country status, and record-comparison questions.

Inspect and download 40 canonical records across FDA-approved medicines, investigational clinical programs, and qualified research-market boards, with aliases, status, evidence coverage, 13 identity-linked trial programs, checked dates, and primary sources.

Obesity and metabolic pipeline. Long-acting amylin analogue · Once-weekly subcutaneous injection. 9 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Petrelintide and cagrilintide are separate investigational long-acting amylin analogues being developed as once-weekly injections for weight management. No head-to-head trial has compared them. Petrelintide has a completed Phase 2 ZUPREME-1 result and a sponsor plan to enter Phase 3 in the second half of 2026. Cagrilintide has a monotherapy arm in Phase 3 REDEFINE 1 and an active standalone RENEW Phase 3 program. Their headline weight-loss percentages came from different trials, durations, populations, estimands, escalation plans, and placebo groups. Neither molecule is FDA approved, and the available records do not establish which is more effective, safer, or more tolerable for an individual.

Compare 3 exact-size PT-141 (Bremelanotide) research listings, including 3 confirmed in-stock rows, the $38.99 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 4 compound-specific country findings.

Audit 2 accepted PT-141 (Bremelanotide) 10 mg price events across 1 seller, plus current matched-market range, availability, sources, and methodology.

PT-141 and Melanotan II share melanocortin-related catalog language and can appear beside one another on research seller sites. This comparison separates their exact identities, aliases, 10 mg price boards, seller overlap, availability, and public evidence routes - and keeps the approved Vyleesi medicine record outside the research-market ranking.

Separate PT-141 and bremelanotide molecular identity from the exact Vyleesi medicine, Phase 3 evidence, early male studies, side effects, research prices, and worldwide verification routes.

Browse exact-size public US research listings with normalized price, availability, evidence-access labels, seller pages, and checked dates.

Obesity and metabolic pipeline. GIP + GLP-1 + glucagon receptor agonist · Once-weekly subcutaneous injection. 34 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Track Retatrutide, Zenagamtide/Amycretin, MariTide, CagriSema, cagrilintide, and Survodutide through Phase 3, application, FDA review, projected windows, and unknown approval dates.

Track current recruiting retatrutide studies, listed countries and US states, active-not-recruiting records, expanded-access limits, and live ClinicalTrials.gov sources.

FDA-approved incretin medicine. Injection · Subcutaneous. NDA 206321 · FDA-approved prescription drug.

FDA-approved melanocortin medicine. Implant · Subcutaneous. NDA 210797 · FDA-approved prescription drug.

Compare 3 exact-size Selank research listings, including 3 confirmed in-stock rows, the $34.99 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 1 compound-specific country findings.

Audit two small Selank anxiety studies, healthy-volunteer brain imaging, ClinicalTrials.gov false matches, FDA compounding history, side-effect limits, current prices, and worldwide status.

Audit 2 accepted Selank 10 mg price events across 1 seller, plus current matched-market range, availability, sources, and methodology.

Selank and Semax are often grouped together as research neuropeptides, yet the public listings represent different synthetic peptide identities and different source records. This page compares their exact-size US research boards, seller overlap, current price ranges, availability, and document-access patterns without converting online claims into efficacy evidence.

Semaglutide and retatrutide have not been compared in a randomized head-to-head trial. Semaglutide is a GLP-1 receptor agonist used in several product-specific approved medicines, including WEGOVY under FDA application NDA 215256. Retatrutide is Lilly's investigational once-weekly GIP, GLP-1, and glucagon receptor triple agonist and is not FDA approved. WEGOVY and STEP evidence and retatrutide's 80-week TRIUMPH-1 result come from separate programs, populations, doses, durations, comparators, and statistical analyses. Those results can explain each evidence record, but they cannot prove that retatrutide is better, safer, more durable, or appropriate for an individual.

Compare 4 exact-size Semax research listings, including 3 confirmed in-stock rows, the $34.11 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 1 compound-specific country findings.

Separate Semax animal findings, healthy-volunteer brain imaging, Russian-language clinical studies, FDA safety findings, current prices, and worldwide status.

Audit 2 accepted Semax 10 mg price events across 1 seller, plus current matched-market range, availability, sources, and methodology.

Compare 3 exact-size Sermorelin research listings, including 2 confirmed in-stock rows, the $43.00 current low, and 1 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 0 compound-specific country findings.

Resolve Sermorelin identity, historical Geref approvals and withdrawals, pediatric studies, modern adult claims, side effects, current prices, molecule comparisons, and worldwide verification routes.

Audit 2 accepted Sermorelin 5 mg price events across 1 seller, plus current matched-market range, availability, sources, and methodology.

Obesity and metabolic pipeline. Glucagon + GLP-1 receptor dual agonist · Once-weekly subcutaneous injection. 31 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Survodutide and retatrutide are different investigational once-weekly obesity programs, and no head-to-head trial has compared them. Survodutide activates glucagon and GLP-1 receptors, while retatrutide also activates the GIP receptor. Both now have Phase 3 obesity results, but the percentages came from separate trials with different durations, dose strategies, populations, estimands, and placebo responses. Survodutide also has a dedicated liver-focused development record. Neither program is approved for marketing, and the current evidence cannot establish which drug is better for an individual.

Compare 8 exact-size TB-500 research listings, including 6 confirmed in-stock rows, the $49.00 current low, and 5 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 2 compound-specific country findings.

Separate the seven-amino-acid TB-500 fragment from full-length thymosin beta-4 trials, then check healing claims, missing human exposure data, side effects, FDA status, and worldwide verification routes.

Audit 3 accepted TB-500 10 mg price events across 2 sellers, plus current matched-market range, availability, sources, and methodology.

Compare 6 exact-size Tesamorelin research listings, including 6 confirmed in-stock rows, the $60.00 current low, and 5 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 2 compound-specific country findings.

Audit 2 accepted Tesamorelin 10 mg price events across 1 seller, plus current matched-market range, availability, sources, and methodology.

Tesamorelin and sermorelin sit in the same broad growth-signaling research family but enter Peptide Local through different exact-size boards and distinct identity records. This comparison shows public US research-market prices, seller coverage, availability, evidence access, and the size mismatch that makes raw vial-price comparisons misleading.